摘要
目的观察利拉鲁肽治疗2型糖尿病合并高脂血症患者的临床疗效。方法选取我院住院治疗的2型糖尿病合并高脂血症患者58例,随机分为利拉鲁肽组(L组,n=29)和胰岛素组(Y组,n=29)。观察和比较两组患者治疗前后空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1C)、血脂(TC、TG、LDL-C、HDL-C)、BMI水平情况。结果两组患者治疗前后的相关指标比较,两组患者治疗后的FBG、2 h PG、Hb A1C、TC、TG、LDL-C、HDL-C、BMI各指标均较治疗前有所改善,差异有统计学意义(P<0.05);利拉鲁肽治疗组的TC、TG、LDL-C、HDL-C、BMI较胰岛素治疗组改善更显著,差异有统计学意义(P<0.05)。结论利拉鲁肽和胰岛素均能改善2型糖尿病合并高脂血症患者的血脂水平,但是利拉鲁肽的效果更显著。
Objective To observe the clinical efficacy of liraglutide treatment combined with hyperlipidemia patients with type 2 diabetes mellitus. Methods 58 cases with hyperlipidemia in patients with type 2diabetes treated in our hospital, were randomly divided into liraglutide group（group L, n=29） and insulin group（group Y, n=29） before and after treatment. The two groups were observed and compared the fasting blood glucose（FBG）, 2 h postprandial blood glucose（2 h PG）, glycosylated hemoglobin（Hb A1C）, blood lipids（TC, TG, LDL-C, HDL-C, BMI） level. Results Compared the related indexes of two groups before and after treatment, two groups of patients with treatment After treatment of FBG, 2 h PG, Hb A1 C, TC, TG, LDL-C, HDL-C, BMI indexes were improved compared with before treatment, the difference was statistically significant（P〈0.05）, liraglutide treatment group TC, TG, LDL-C, HDL-C, BMI compared with the insulin treatment group improved more significantly, the difference was statistically significant（P〈0.05）. Conclusion Liraglutide and insulin in patients with type 2 diabetes can improve the blood lipid level in patients with hyperlipidemia, but the liraglutide effect is more significant.
出处
《中国继续医学教育》
2016年第36期111-113,共3页
China Continuing Medical Education
